PBYI Q4 2018 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+229.2% YoY

Gross Profit

$61M85.5% margin

Operating Income

-$19M-26.2% margin

Net Income

-$31M-43.2% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+13.6%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$7M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$259M

Total Liabilities

$225M

Stockholders' Equity

$34M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$22M	+229.2%
Gross Profit	$61M	$18M	+247.4%
Operating Income	-$19M	-$64M	+70.8%
Net Income	-$31M	-$64M	+52.1%

Revenue Segments

Product

$61M86%

License

$10M14%